Renal
Chronic Hyperkalaemia Management
Long-term management in CKD/HF — dietary, drugs, potassium binders to enable RAAS continuation.
Source: Renal Association 2020; NICE TAs
Step 1 of ~3
info
Identify Persistent Mild–Moderate Hyperkalaemia (5.5–6.5)
Common in CKD (especially eGFR <30), HF on RAAS therapy, diabetes. Confirm true (not haemolysed sample). Exclude AKI. Review medications: ACE-I/ARB, MRA (spironolactone, eplerenone), trimethoprim, NSAIDs, beta-blockers, heparin, calcineurin inhibitors, K-sparing diuretics, K-containing salt substitutes.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Pancuronium · Non-Depolarising Neuromuscular Blocking Agent (Long-Acting)
- Potassium Chloride (IV) · Electrolyte — Potassium Supplement
- Insulin (IV Infusion — ICU Glucose Control) · Insulin — ICU Glucose Management
- Sodium Chloride 3% (Hypertonic Saline) · Hypertonic Electrolyte Solution — ICP/Hyponatraemia Management
- Pancuronium bromide · Long-acting non-depolarising neuromuscular blocker
- Ropivacaine hydrochloride · Long-acting amide local anaesthetic
Pathways
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019
Decision support only. Always apply local guidelines and clinical judgement.